Skip to content
ModernDocHealth
Contact

Skip to section

Hepatology

What the Latest Research Reveals

Data last updated: 37 studies cited

How this page is produced

Generated by the ModernDoc Research Monitor from peer-reviewed literature. Every statistic is automatically checked against its cited source and screened for retractions before it is published. This page is AI-generated and has not yet been reviewed by a clinician — it is not medical advice. Read how we build and check these pages.

25-30%
of hospitalized COVID-19 patients develop liver enzyme abnormalities
— rising to 45-52% in severe cases
Source: Kulkarni et al.. Alimentary Pharmacology & Therapeutics (2020). 10.1111/apt.15916 | n=18402

KEY FINDINGS

Elevated AST
29.1%
95% CI: Prevalence (95% CI: 24.5-33.9%)
Source [1]
Cirrhosis Mortality
2.48x
95% CI: OR 2.48 (95% CI: 1.78-3.47)
Source [7]
MAFLD Severe COVID Risk
2.15x
95% CI: OR 2.15 (95% CI: 1.58-2.93)
Source [5]
Severe Disease Liver Injury
3.21x
95% CI: OR 3.21 (95% CI: 2.36-4.37)
Source [1]

THE TIMELINE

Acute Phase

Days 0-14

Days 5-10 after symptom onset

Key Event
Peak liver enzyme elevation

Liver Function Abnormality Rates

Source: Meta-analyses vs pre-pandemic general population data

Cumulative Risk with Reinfection

Index Infection+25-30%
Reinfection+Cumulative organ risk
Multiple Infections+Accelerated fibrosis concern

“Repeated hepatic inflammation may accelerate fibrosis progression”

THE HOPEFUL HORIZON

  • Vaccination is safe and effective in chronic liver disease patients (85-90% seroconversion)[29]
  • Most liver enzyme elevations resolve within 4-6 weeks[1]
  • Drug-induced severe hepatotoxicity remains uncommon (<2%)[12]
  • UDCA users showed 46% lower COVID-19 mortality (OR 0.54)[24]

SOURCES

  1. [1]Kulkarni AV, Kumar P, Sharma M, et al. Systematic review with meta-analysis: liver manifestations and outcomes in COVID-19. Alimentary Pharmacology & Therapeutics. 2020;52(4):584-599. DOI (opens in new tab)
  2. [2]Sultan S, Altayar O, Siddique SM, et al. AGA Institute Rapid Review of the GI and Liver Manifestations of COVID-19. Gastroenterology. 2020;159(1):320-334.e27. DOI (opens in new tab)
  3. [3]Mao R, Qiu Y, He JS, et al. Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19. Lancet Gastroenterology & Hepatology. 2020;5(7):667-678. DOI (opens in new tab)
  4. [4]Singh S, Khan A. Clinical Characteristics and Outcomes of Coronavirus Disease 2019 Among Patients With Preexisting Liver Disease. Gastroenterology. 2020;159(2):768-771.e3. DOI (opens in new tab)
  5. [5]Pan L, Huang P, Xie X, et al. Metabolic-associated fatty liver disease increases the severity of COVID-19: A meta-analysis. Hepatology International. 2021;15:1-10. DOI (opens in new tab)

See a problem with the Hepatology research summary?

Send a source correction or freshness concern. We cannot provide personal medical advice through this site.

Report a correction

SHARE THIS INFORMATION

Share with someone who needs to know

Back to DashboardReport an Issue

Data last updated:

Medical review: AI-generated — pending clinician review

Sources cited: 37 peer-reviewed sources

Claim verification: 0/0 verified (NaN%)

About DOIs

This information is for educational purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider for medical decisions. Data is sourced from peer-reviewed publications and may be updated as new research emerges.